Average Co-Inventor Count = 2.34
ph-index = 2
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Pierre Fabre Medicament (8 from 266 patents)
2. Cvasthera (0 patent)
8 patents:
1. 10265322 - Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions
2. 9980970 - Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions
3. 9603835 - Use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine for treating cancer and in particular for preventing and/or treating cancer metastases
4. 9433603 - Use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine for preventing and/or treating cardiotoxic effects caused by chemotherapy and/or radiation
5. 9393228 - Combination of a slow sodium current blocker and a sinus If current inhibitor, and the pharmaceutical compositions containing said combination
6. 8513258 - Cinnamoyl-piperazine derivatives and their use as par-1 antagonists
7. 8217046 - Cinnamoyl-piperazine derivatives and their use as PAR-1 antagonists
8. 8022064 - Phenylpentadienoyl derivatives and their use as PAR 1 antagonists